Uncover key drivers, emerging technologies, and competitive movements shaping the nucleic acid therapeutics market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Nucleic Acid Therapeutics Market Today And What Is Its Future Size?

The nucleic acid therapeutics market has experienced substantial expansion in recent years. Its value is projected to increase from $6.01 billion in 2024 to $6.94 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.6%. This historical development has been influenced by several key factors, including the rising incidence of genetic and chronic ailments, intensified research and development within genomics, the growing acceptance of RNA-based therapies, increased backing from academic and government organizations, and the notable achievements of mRNA vaccine platforms.

The nucleic acid therapeutics market is projected to experience substantial expansion over the upcoming years, reaching $12.24 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.2%. This anticipated growth during the forecast period is fueled by several factors, including the increasing need for precision medicine, the broadening scope of mRNA vaccine applications beyond COVID-19, the emergence of advanced delivery platforms, an expanding array of nucleic acid-based drugs in development, and a rise in regulatory approvals. Key developments expected in the forecast period encompass the extension of mRNA platforms into cancer treatment and rare conditions, the incorporation of AI and machine learning into the discovery process for RNA drugs, the creation of specific delivery systems designed for tissue-targeted action, the advent of modular and multi-target therapeutic platforms, and advancements in next-generation aptamer technologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp

Which Demand Drivers Are Strengthening The Nucleic Acid Therapeutics Market?

The rising prevalence of genetic and chronic diseases is projected to stimulate the expansion of the nucleic acid therapeutics market in the future. These conditions involve the link between inherited genetic factors and the development, progression, or risk of long-term health issues, including diabetes, cardiovascular diseases, cancer, and autoimmune disorders. The increase in genetic and chronic diseases is largely attributable to advancements in diagnostic technologies, which allow for more accurate and earlier identification of these conditions. Nucleic acid therapeutics prove beneficial for genetic and chronic diseases because they can target and modify the underlying genetic causes by regulating, repairing, or silencing specific genes, thereby offering precise and personalized treatment options. For instance, in October 2024, data from the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, showed that registered cystic fibrosis patients increased from 11,148 in 2022 to 11,318 in 2023, marking a 1.5% year-over-year rise in patient registrations. Thus, the growing number of genetic and chronic diseases is propelling the growth of the nucleic acid therapeutics market.

Which Segment Accounts For The Largest Share In The Nucleic Acid Therapeutics Market?

The nucleic acid therapeutics market covered in this report is segmented

1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types

2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas

3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations

4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems

5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies

Subsegment:

1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs

2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA

3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs

4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers

5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes

Which Long-Term Trends Will Play A Crucial Role In The Nucleic Acid Therapeutics Market?

Major companies within the nucleic acid therapeutics market are concentrating on developing innovative products, such as antisense oligonucleotide therapy, to target and silence specific disease-causing genes, thereby offering precision treatment options for genetic disorders and rare diseases. This therapy is a precision treatment that utilizes short, synthetic strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to block or modify the expression of specific genes implicated in disease. For instance, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for TRYNGOLZ (olezarsen) to be used as an adjunct therapy to diet for lowering triglyceride levels in adults diagnosed with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe hypertriglyceridemia (sHTG) and a high risk of acute pancreatitis (AP). This drug represents the first FDA-approved treatment capable of delivering significant and sustained triglyceride reduction in this patient population, alongside a clinically meaningful decrease in AP incidence when combined with a low-fat diet. The therapy is designed for convenient self-administration through a once-monthly auto-injector.

Which Companies Hold A Competitive Edge In The 173 Market?

Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Moderna Inc., BioNTech SE, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Imugene Limited, CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc., and Exothera S.A.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-therapeutics-global-market-report

Which Region Is Forecasted To Lead The Nucleic Acid Therapeutics Market In The Coming Years?

North America was the largest region in the nucleic acid therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27368&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Therapeutics Market 2025, By The Business Research Company

Sandwich Panels Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sandwich-panels-global-market-report

Metal Structural Insulation Panels Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metal-structural-insulation-panels-global-market-report

Building Insulation Materials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/building-insulation-materials-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model